Effect of a somatostatin analogue (SMS 201–995) on renal function and urinary protein excretion in diabetic rats

Igarashi, Kazumasa; Nakazawa, Akiko; Tani, Nagayuki; Yamazaki, Masatoshi; Ito, Seiki; Shibata, Akira

doi:10.1016/0891-6632(91)90066-x

Cited by 12 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When octreotide treatment for 14 weeks was initiated in unilateral nephrectomized diabetic rats on the day of diabetes induction 3 days after unilateral nephrectomy, Muntzel et al (1992) observed no effect of octreotide treatment on renal hypertrophy, UAE or glomerular hyperfiltration. The lack of effect of octreotide treatment on renal hypertrophy may be due to the late intervention when IGF-I accumulation has already peaked following nephrectomy and ongoing renal growth (Flyvbjerg et al 1988), or to the low octreotide dose used (Flyvbjerg et al 1990). Igarashi et al (1991 observed diminished kidney hypertrophy and albuminuria in uninephrectomized diabetic rats following an untreated diabetes period of 15 weeks.…”

Section: Discussionmentioning

confidence: 99%

Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention

Grønbæk

Nielsen²,

Frystyk³

et al. 1995

Journal of Endocrinology

View full text Add to dashboard Cite

IGF-I acts as a renotropic factor in early streptozotocin-induced diabetes. Somatostatin analogue (octreotide) treatment initiated at the onset of diabetes prevents kidney IGF-I accumulation and renal growth. Seven days of octreotide treatment initiated after 3, 5, 7 or 9 days of untreated diabetes was investigated. Diabetic renal hypertrophy was followed by renal hyperplasia. Compared with placebo-treated diabetic rats, the earliest octreotide intervention was followed by a greater reduction in renal growth compared with intervention later on (days 3 to 10, 12%; days 5 to 12, 10%; days 7 to 14, 9%; days 9 to 16, 6%; P < 0.05). Octreotide treatment was unable to reduce protein accumulation and kidney DNA increase consistently. No difference in glomerular volume fraction or total glomerular volume was observed between placebo- and octreotide-treated diabetic rats. Octreotide treatment was followed by reduced kidney and serum IGF-I especially following early intervention, while no effect over that of diabetes was observed in the later intervention periods. The results confirm the notion that initial renal IGF-I accumulation is a prerequisite for early diabetic kidney hypertrophy in rats and show that delayed octreotide treatment cannot reverse renal and glomerular growth which is already manifest.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention

Grønbæk

Nielsen²,

Frystyk³

et al. 1995

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…When octreotide treatment for 14 weeks was initiated in unilaterally nephrectomized diabetic rats on the day of diabetes induction 3 days after the nephrectomy, no effect of octreotide treatment on renal hypertrophy, AER or glomerular hyperfiltration was, however, observed [64]. In some studies [65,66] octreotide treatment for 2±3 weeks was followed by diminished kidney hypertrophy and albuminuria in uninephrectomized-diabetic rats after 15 weeks of untreated diabetes. A recent study from our group aimed at examining the effect of 3 weeks of treatment with octreotide and an angiotensin-converting enzyme inhibitor (ACEi) (captopril) either alone or in combination after 3 months of untreated diabetes [67].…”

Section: Agents With Effects On the Altered Gh/igf Axis In Diabetic Kmentioning

confidence: 99%

Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

2000

View full text Add to dashboard Cite

“…In the studies cited above [9,15,34,35] octreotide treatment was initiated on the day of diabetes induction but only a single study has previously been conducted on octreotide intervention later in the diabetic period when renal pathological changes had become manifest. Igarashi et al [37] treated uninephrectomized-diabetic rats with octreotide for 3 weeks after 15 weeks of untreated diabetes and observed diminished kidney hypertrophy and albuminuria. This is partly in contrast to the results of the present study in which we only find a trend towards diminished kidney weight and no effect on UAE.…”

Section: Discussionmentioning

confidence: 99%

Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats

et al. 1995

View full text Add to dashboard Cite

Summary Treatment of diabetic rats with octreotide can inhibit early diabetic renal hypertrophy. Octreotide administration for 6 months from the day of diabetes induction inhibits renal hypertrophy and diminishes increase in urinary albumin excretion. To investigate the effect of octreotide on manifest diabetic renal changes, octreotide treatment was given for 3 weeks after an untreated diabetic period of 3 or 6 months. In addition, following 6 months of diabetes, a group of diabetic rats was treated with insulin for 3 weeks. Renal and glomerular hypertrophy, and increased urinary albumin excretion were observed in diabetic rats compared to non-diabetic control rats from 3 months and throughout the study period. Octreotide treatment did not affect body weight, food intake, blood glucose or serum fructosamine levels. We observed no effect of octreotide treatment on renal and glomerular hypertrophy or urinary albumin excretion compared to placebotreated diabetic rats. Insulin treatment for 3 weeks after 6 months of untreated diabetes normalized blood glucose and serum fructosamine levels, and furthermore renal hypertrophy was significantly diminished compared to the placebo-treated diabetic rats. However, insulin treatment had no effect on glomerular hypertrophy or urinary albumin excretion. In conclusion, octreotide treatment for 3 weeks following an untreated diabetic period of 3 or 6 months is unable to reduce the increased renal and glomerular volume or urinary albumin excretion. However, insulin treatment for 3 weeks with induction of euglycaemia diminishes the renal hypertrophy but has no effect on glomerular volume or urinary albumin excretion. [Diabetologia (1995) 38: 135-144]

show abstract

Effect of a somatostatin analogue (SMS 201–995) on renal function and urinary protein excretion in diabetic rats

Cited by 12 publications

References 7 publications

Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention

Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention

Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats

Contact Info

Product

Resources

About